Attila Vajas

Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes

2023 | Central Library of Charles University, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové